Clinical Trial Update: Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) [Phase 3]

View source ↗

Summary

A Phase 3 trial of the Grazoprevir/elbasvir combination in treatment-naïve hepatitis C patients has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Zepatier (elbasvir/grazoprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2017-10-17